Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EYP001a + peginterferon alfa-2a + entecavir
- Development stage
- Unknown
- Lead developer
- ENYO Pharma
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
EYP001a + peginterferon alfa-2a + entecavir is an investigational oral combination therapy for chronic hepatitis B (CHB) and potentially other liver diseases. EYP001a is a small molecule farnesoid X receptor (FXR) agonist that modulates bile, lipid, and glucose metabolism and is being developed for antiviral and hepatoprotective activity[7][1][5]. Peginterferon alfa-2a is a recombinant interferon that stimulates the innate antiviral response via the JAK/STAT pathway and is approved for hepatitis B and C treatment[2][4][6]. Entecavir is a nucleoside analogue antiviral agent inhibiting hepatitis B virus polymerase. The combination aims for functional cure by targeting multiple viral and host pathways.
- Brand names
- PegasysBaraclude
- Other names
- vonafexorentecavir
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)HBV Pol (Hepatitis B virus polymerase)FXR (Farnesoid x-activated receptor)
Beyond the preview
Go deeper on EYP001a + peginterferon alfa-2a + entecavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EYP001a + peginterferon alfa-2a + entecavir.